Drug intelligence / Profile preview

ANC-1

Development stage: Preclinical
Lead developer: Aix-Marseille University
Modality: Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

ANC-1 (antibody nanoconjugate-1) is a preclinical-stage antibody-targeted nanoparticle (immunoliposome) developed for the treatment of HER2-positive breast cancer. It consists of the chemotherapeutic agent docetaxel encapsulated within a pegylated (stealth) liposome, which is covalently engrafted with the anti-HER2 monoclonal antibody trastuzumab on its surface. This design is intended to improve the therapeutic index of the docetaxel-trastuzumab combination by enhancing drug trafficking, tumor-specific delivery, and cellular uptake via receptor-mediated endocytosis, thereby reducing systemic toxicities associated with the standard doublet therapy.

Other names: antibody nanoconjugate-1docetaxel trastuzumab stealth immunoliposometrastuzumab-docetaxel immunoliposome

Targets

TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on ANC-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANC-1.

Explore the full profile